Back to Search Start Over

Preliminary Evidence of Efficacy, Safety, and Treatment Satisfaction with Tirbanibulin 1% Ointment: A Clinical Perspective on Actinic Keratoses

Authors :
Elena Campione
Antonia Rivieccio
Ruslana Gaeta Shumak
Gaetana Costanza
Terenzio Cosio
Sara Lambiase
Virginia Garofalo
Fabio Artosi
Flavia Lozzi
Claudia Freni
Alice Romeo
Emi Dika
Mattia Falconi
Luca Bianchi
Source :
Pharmaceuticals, Vol 16, Iss 12, p 1686 (2023)
Publication Year :
2023
Publisher :
MDPI AG, 2023.

Abstract

Background: Actinic keratosis is a common precancerous skin lesion that can progress into invasive squamous cell carcinomas. Many topical treatments for actinic keratoses often have poor tolerability and prolonged duration. Tirbanibulin is a novel synthetic drug with potent antitumor and antiproliferative activities. Methods: We conducted a single-center, prospective and observational study using tirbanibulin ointment on a 25 cm2 area for 5 consecutive days on 30 participants with AKs on the face or scalp. They were followed for at least 57 days to assess the safety profile and efficacy of the drug as well as treatment satisfaction. We evaluated six signs of local skin reaction (LSR): erythema, scaling, crusting, swelling, blisters/pustules, and erosions/ulcerations, grading the severity as mild, moderate, or severe. The effectiveness was evaluated both clinically and dermoscopically. The treatment satisfaction was assessed using the Treatment Satisfaction Questionnaire for Medication (TSQM 1.4). Results: On day 57, 70% of the patients showed a complete clinical and dermoscopic response. The highest scores obtained from the TSQM 1.4 were more evident in the convenience and side effects domains. Most LSRs, including erythema (83.3%), scaling (30%), and swelling (3.3%), occurred on day 8 but resolved spontaneously. Conclusion: Tirbanibulin is a viable therapeutic option with a short regimen treatment and good tolerability, which favors therapy adherence.

Details

Language :
English
ISSN :
16121686 and 14248247
Volume :
16
Issue :
12
Database :
Directory of Open Access Journals
Journal :
Pharmaceuticals
Publication Type :
Academic Journal
Accession number :
edsdoj.201d9c17c2d0444593057758b0bea404
Document Type :
article
Full Text :
https://doi.org/10.3390/ph16121686